Free Trial
NASDAQ:INMB

INmune Bio (INMB) Stock Price, News & Analysis

INmune Bio logo
$0.96 -0.09 (-8.48%)
As of 02:23 PM Eastern
This is a fair market value price provided by Massive. Learn more.

About INmune Bio Stock (NASDAQ:INMB)

Advanced

Key Stats

Today's Range
$0.89
▼
$1.06
50-Day Range
$1.05
▼
$2.51
52-Week Range
$0.89
▼
$2.60
Volume
341,579 shs
Average Volume
479,703 shs
Market Capitalization
$29.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.50
Consensus Rating
Moderate Buy

Company Overview

INmune Bio, Inc. is a clinical-stage biotechnology company developing treatments that target the innate immune system. The company’s research focuses on using immune responses to address cancer and inflammatory conditions, including neuroinflammation.

Its pipeline includes XPro1595, a selective inhibitor of soluble tumor necrosis factor being studied for conditions including Alzheimer’s disease, and INKmune, an investigational cell therapy designed to enhance natural killer cell activity against cancer. These therapies remain under clinical development.

INmune Bio is headquartered in La Jolla, California. The company is led by Raymond J. Tesi, M.D., its co-founder, president and chief executive officer.

AI Generated. May Contain Errors.

INmune Bio Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
42nd Percentile Overall Score

INMB MarketRank™: 
2.111228953995 of 5 stars

INmune Bio scored higher than 42% of companies evaluated by MarketBeat, and ranked 694th out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    INmune Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 1 buy rating, no hold ratings, and 1 sell rating.

  • Upside Potential

    INmune Bio has a consensus price target of $2.50, representing about 175.6% upside from its current price of $0.91.

  • Amount of Analyst Coverage

    INmune Bio has only been the subject of 2 research reports in the past 90 days.

  • Read more about INmune Bio's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of INmune Bio is -1.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of INmune Bio is -1.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    INmune Bio has a P/B Ratio of 1.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    10.93% of the float of INmune Bio has been sold short.
  • Short Interest Ratio / Days to Cover

    INmune Bio has a short interest ratio ("days to cover") of 14.4, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in INmune Bio has recently decreased by 7.89%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    INmune Bio does not currently pay a dividend.

  • Dividend Growth

    INmune Bio does not have a long track record of dividend growth.

  • News Sentiment

    INmune Bio has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for INmune Bio this week, compared to 2 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, INmune Bio insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    21.40% of the stock of INmune Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    12.72% of the stock of INmune Bio is held by institutions.

  • Read more about INmune Bio's insider trading history.
Receive INMB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for INmune Bio and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

INMB Stock News Headlines

INmune Bio (NASDAQ:INMB) Rating Lowered to "Sell" at Wall Street Zen
Why my scanner is $7
Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full year, with no re-bills and nothing to install. The catch? He isn't trying to profit on the scanner itself. Poulos is betting that once you see it deliver the night's list, you'll want more of his work for years.tc pixel
See More Headlines

INMB Stock Analysis - Frequently Asked Questions

INmune Bio's stock was trading at $1.56 at the beginning of 2026. Since then, INMB stock has decreased by 41.9% and is now trading at $0.9070.

INmune Bio, Inc. (NASDAQ:INMB) issued its quarterly earnings data on Thursday, November, 5th. The company reported ($0.17) EPS for the quarter, missing analysts' consensus estimates of ($0.15) by $0.02.
Read the conference call transcript
.

INmune Bio (INMB) raised $20 million in an initial public offering (IPO) on the week of February 4th 2019. The company issued 2,500,000 shares at a price of $8.00 per share.

Top institutional investors of INmune Bio include State Street Corp (0.42%), Marshall Wace LLP (0.29%) and Russell Investments Group Ltd. (0.09%). Insiders that own company stock include Raymond Joseph Tesi, David J Moss and Scott Juda.
View institutional ownership trends
.

Shares of INMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that INmune Bio investors own include Cassava Sciences (FLNA), NVIDIA (NVDA), Palantir Technologies (PLTR), Plug Power (PLUG), PayPal (PYPL), Advanced Micro Devices (AMD) and CrowdStrike (CRWD).

Company Calendar

Last Earnings
11/05/2026
Today
11/16/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:INMB
CIK
1711754
Fax
N/A
Employees
21
Year Founded
N/A

Price Target and Rating

High Price Target
$2.50
Low Price Target
$2.50
Potential Upside/Downside
+170.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.60)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$45.93 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-81.71%
Return on Assets
-62.58%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.41
Quick Ratio
6.41

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.88 per share
Price / Book
1.05

Miscellaneous

Outstanding Shares
30,959,000
Free Float
24,334,000
Market Cap
$28.67 million
Optionable
Optionable
Beta
0.97
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

This page (NASDAQ:INMB) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners